News One of J&J's blockbuster depression hopes has flamed out Johnson & Johnson has halted the development of aticaprant as a treatment for major depressive disorder, blowing a hole in its late-stage pipeline.
News J&J shares data on would-be blockbuster antidepressant Johnson & Johnson’s seltorexant is one of two new therapies that the company reckons could become blockbuster treatments for depression, and data from a phase 3 trial
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.